Abstract
The immunosuppressants tacrolimus (FK506) and cyclosporin A (CsA) have increased the survival rates in organ transplantation. Both drugs inhibit the protein phosphatase calcineurin (CaN) in activated T cells, exhibiting similar side-effects. Diabetes is observed more often in FK506 than CsA therapy, probably due to inhibition of new molecular targets other than CaN. We studied FK506 toxicity in mammalian cells. FK506, but not CsA, regulated p38 activation by osmotic stress, and decreased viability in osmostressed cells. In addition, FK506 treatment strongly increased the phosphorylation of the eukaryotic initiation factor-2a (eIF-2a) subunit. eIF-2a phosphorylation, p38 inhibition and cell lethality were relieved by addition of excess amino acids to the medium, suggesting that amino acid availability mediated FK506 toxicity. Therefore, these FK506-dependent responses could be relevant to the non-therapeutic effects of FK506 therapy.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 16 October 2003; received after revision 8 January 2004; accepted 14 January 2004
Rights and permissions
About this article
Cite this article
Sanchez-Perez, I., Rodriguez-Hernandez, C.J., Manguan-García, C. et al. FK506 sensitizes mammalian cells to high osmolarity by modulating p38 MAP kinase activation. CMLS, Cell. Mol. Life Sci. 61, 700–708 (2004). https://doi.org/10.1007/s00018-003-3388-x
Issue Date:
DOI: https://doi.org/10.1007/s00018-003-3388-x